All cell types found in the body are derived from stem cells. However, genetic mutations can impact the ability of stem cells to develop into fully functional cells. Also, as the body ages, the number ...

Motixafortide alone and in combination with natalizumab can support the collection of the large number of stem cells required by gene therapies for sickle cell disease within a single apheresis cycle ...

Phase 2 data showed rapid increases in CD34+ stem cells, allowing same-day dosing and collection. ・Daratumumab-treated patients, who often struggle with mobilization, also achieved strong collection ...

The UK's first stem cell collection centre strictly dedicated to transplants has started welcoming donors. The Anthony Nolan Cell Collection Centre, based at Nottingham's Queen's Medical Centre (QMC), ...

Key Highlights Motixafortide effectively mobilized sufficient hematopoietic stem cells (HSCs) in patients with sickle cell disease enabling accelerated access to gene therapies 90% (9 of 10) of ...

Stem cells can fight disease from the inside out. But not all treatments are created equal. By Mohana Ravindranath The promise of stem cell therapy is powerful. Scientists can draw versatile cells ...

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a critical therapeutic strategy for treating conditions such as hematological malignancies, bone marrow failure syndromes, and ...

Stem cells elicit immunomodulatory properties through surface protein expression and their secretome. These properties allow stem cells to influence the ...

Stem cell therapy is an emerging treatment for type 2 diabetes. Although it’s not yet FDA-approved in the United States, it is a rapidly expanding and promising field of research. Stem cells are ...

Jennifer Zenker receives funding from NHMRC and Viertel Foundation. Most people have heard of stem cells. They are often described as “miracle” cells –ones that can grow into any other type of cell in ...

CAMBRIDGE, Mass., Dec. 06, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced new ...